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1. Introduction 
Diabetes and its micro- and macro-vascular complications constitute one of the principal 
social-health problems world-wide. It has high impact on the quality of life and prognosis of 
the individuals affected, as well as high direct and indirect economic costs to the Public 
Health Service. Following the publication of benchmark studies in the 1990s which indicated 
that the maintenance of glycaemia levels as close as possible to normality is associated with 
a lower incidence, progression and severity of the complications, the optimisation of 
metabolic control has been converted to a core therapeutic objective (DCCT, 1993; Herman, 
1999; UKPDS, 1998). The tools for the management of diabetes have advanced spectacularly 
in these past few years, not only for the control of glycaemia but also for its measurement. 
As such, currently, there is a wide variety of drugs available with different mechanisms of 
action which, alone or in combination, enable a reasonable metabolic control in the majority 
of cases. Although insulin has been used for >80 years, the biggest advances in the mode of 
use have been over the last two decades. This change has been due, in great part, to: 1) 
development of new sources of insulin (analogues of insulin) together with the development 
and fine-tuning of different forms of its administration (continuous subcutaneous insulin 
infusion; CSII) in search of profiles of activity closer to the normal physiologic state; 2) 
change in philosophy in the therapeutic planning of diabetes, such that the strategies of co-
responsibility and flexibility of life-style have become fundamental aspects;  3) introduction 
of self-control using capillary glycaemia (SCCG) in daily practice (De Witt & Hirsch, 2003); 
4) recent incorporation in clinical practice of the use of glucose sensors, continuous glucose 
monitoring systems (CGMS) that generate the maximum information on modifications of 
glucose levels in plasma along the course of the whole day.  
This review centres on the importance, in clinical practice, of the metabolic control targets 
for patients with DM type 1. Difficulties in achieving glycaemia goals using multiple insulin 
injection with new insulin analogues, and modern technologies such as CGMS and CSII are 
extensively analysed.  
2. Importance of glycaemia control in the treatment of diabetes 
Traditionally, the conventional therapy has been orientated towards achieving acceptable 
levels of glycaemia and stable clinical status in the asymptomatic patient. Intensive 
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treatment of diabetes, according to the protocol of the Diabetes Control and Complications 
Trial (DCCT), consists in a therapeutic design orientated towards achieving almost normal 
levels of glycaemia. Included are: a rigorous educative plan with frequent actions for a life-
style change, an insulin regimen with three or more daily injections (multiple doses of 
insulin), or CIIS and programme of SCCG four of more per day (DCCT, 1995).  
Over the past few years there have been several studies evaluating the effect on the 
appearance and progression of the micro-vascular complications of diabetes using a strict 
control of glycaemia with intensive treatment (Herman, 1999). The most significant was the 
DCCT study published in 1993 (DCCT, 1993). Included were more than 1000 patients with DM 
type I and the results demonstrated that maintaining the levels of glucose within a range 
closest to normality, tended to reduce the appearance of retinopathy by 76%, nephropathy by 
56% and neuropathy by 60%. The DCCT established the targets of glycaemia control and of 
glycosylated haemoglobin (HbA1c) in patients with DM type 1, together with the need to 
perform measurement of capillary glycaemia as part of the intensive treatment regimen.  
In DM type 2, the Kumamoto study (Shichiri et al., 2000) with a design similar to the DCCT, 
demonstrated that intensive treatment (target of HbA1c <7%) reduced the risk of 
retinopathy by 69% and nephropathy by 70%. The United Kingdom Prospective Diabetes 
Study (UKPDS) published in 1998, demonstrated that intensive long-term treatment of the 
hyperglycaemia also reduced the appearance of micro-vascular complication in patients 
recently diagnosed with DM type 2 (UKPDS, 1998). 
These studies demonstrated definitively that the better the control of glycaemia the tighter 
the association with the decrease in the rates of micro-vascular complications (retinopathy 
and nephropathy). Follow-up studies of the DCCT (DCCT-EDIC; 2000; Martin et al., 2006) 
and of the UKPDS (Holman et al., 2008) have highlighted that once the intensive treatment 
is established in the two groups with evidence of their benefits, those that had been 
performed earlier retain their benefits as the product of a “metabolic legacy”. 
Despite that many epidemiologic studies and meta-analyses (Selvin et al., 2004;  Stettler et 
al., 2006) having clearly demonstrated a direct relationship between HbA1c and the 
incidence of cardiovascular disease (CVD), the potential of intensive control of glycaemia to 
reduce CVD has not been delineated, as yet. In the DCCT, no differences were observed 
between the groups with respect to the appearance of CVD events. However, at 8 years of 
conclusion of the study, the patients who had been assigned to the intensive treatment 
group had a 42% reduction in CVD and a 57% reduction in the risk of non-fatal myocardial 
infarction, stroke or death, compared to those who had been assigned to the standard 
treatment arm of the trial (Nathan et al., 2005). It has been demonstrated recently that, as 
with DM type 2, the benefit of intensive glycaemia control in patients with DM type 1 
persists over decades (DCCT-EDIC, 2009). 
In the UKPDS, a reduction was observed of 16% in the risk of CVD in the intensive 
treatment group, although this difference did not reach statistical significance. However,  at 
10 years of follow-up, a reduction in non-fatal acute myocardial infarction and in all-cause 
mortality of 13 and 27%, respectively (Holman et al., 2008) was demonstrated in the 
participants initially assigned to intensive control of glycaemia, compared to those assigned 
to conventional control. Nevertheless, the results of three large studies (ACCORD, Ismail-
Beigi et al., 2010; ADVANCE, Patel et al., 2008; VADT, Duckworth at al., 2009) that had 
investigated the effect of glycaemia control in DM type 2, were unable to demonstrate that 
the intensive control of glycaemia achieved any reduction in the CVD, even though the 
patients were DM type 2 of long duration and with high risk of CVD. 
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Maintaining levels of glycaemia that are practically normal carries a series of notable risk. 
Among these is the increase in episodes of slight as well as of severe hypoglycaemia. The 
investigators in the EDIC study (Nathan et al., 2005) observed CVD benefits associated with 
intensive glycaemia control, but not in those with a level of HbA1c <6.5%. In the initial 
publications of the ACCORD study, the greater rates of mortality were produced in the 2 
extreme categories of HbA1c, independently of the regimen of treatment. Also, the 
decreases in survival in the patients with lower HbA1c levels were related, at least in part, to 
the appearance of hypoglycaemia. As such, episodes of severe hypoglycaemia in patients 
with advanced disease need to be prevented, and not with the intention of achieving 
normal, or near normal, levels of HbA1c (<6.5%) in those in whom achieving normal levels 
safely do not appear probable. 
2.1 Objectives of glycaemia control 
The recommendations for glycaemia control targets in adults, in pregnant and in non-pregnant 
women are shown in Table 1. The recommendations are based on the blood levels of glucose 
which correlate with levels of HbA1c at 7%. The targets need to be individualised for each 
patient, and it is necessary to be assured of achieving them. In young and healthy patients that 
know the symptoms of hypoglycaemia and recover from them relatively easily, the targets 
need to approximate to the levels of glycaemia observed in persons without diabetes. 
However, the objectives of control are more strict during gestation, and more permissive for 
persons who have difficulties noting the symptoms of hypoglycaemia as well as those who 
present with severe hypoglycaemia or for those whose episodes of hypoglycaemia can be 
particularly dangerous (for example, patients with heart disease, cerebrovascular pathology or 
autonomic neuropathy). As such, in adults with limited life expectancy or advanced vascular 
disease, it would be more appropriate to have less strict targets. Post-prandial hyperglycaemia 
is defined as values of glycaemia >140 mg/dL at two hours after a meal. It is a frequent 
phenomenon that is unnoticed in the determination of HbA1c and basal glycaemia since it is 
already present when the levels of HbA1c are optimum. Several studies have shown that the 
levels of post-prandial glycaemia are strongly related to the CVD risk (Cavalot et al., 2006; 
Ceriello, 2005; European Diabetes Epidemiology Group, 1999; ). Curiously, the contribution of 
post-prandial glycaemia appears to be more evident in patients with well-controlled diabetes 
(contribution of about 70% to the HbA1c when it is <7% and about 40% when it is >7.3%). 
However, the targets of post-prandial glycaemia using SCCG are controversial. In some 
epidemiology studies, values of elevated glucose following oral glucose load test have been 
associated with an increased risk of CVD, independently of the fasting plasma glucose level. 
Also, the phenomenon appears intimately linked with CVD such as endothelial dysfunction 
which is aggravated by post-prandial hyperglycaemia (Ceriello et al., 2002). The majority of 
authors recommend values of HbA1c <7% as the appropriate metabolic control objective 
(American Diabetes Association, 2011)   
Achieving a good metabolic control in DM type 1 is not an easy issue. Results reported in 
international studies on the degree of metabolic control in 13,612 patients from Sweden 
(Katarina et al., 2007) and 27,035 from Austria and Germany (Gerstl et al., 2008) showed that 
only 21.2% and 27%, respectively, of type 1 DM patients have HbA1c <7%. We studied a 
cohort of patients with type 1 DM (n = 489) followed-up from 2005 to 2007. During the study 
period, the mean HbA1c decreased from 7.78% to 7.36% and the frequency of patients with 
HbA1c <7% increased from 24.6% to 27.1% and those with a mean HbA1c of >8% decreased 
from 42.6% to 38.7% (Baena et al., 2008). 
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HbA1c < 7% 
Pre-prandial plasma glucose 70-130 mg/dL 
Post-prandial plasma glucose <180 mg/dL 
The objectives need to be individualised based on: 
• Duration of the diabetes 
• Life expectancy 
• Associated co-morbidities 
• Known CVD or advanced micro-vascular complications 
• Severe hypoglycaemia, or inadvertent 
To improve objectives of post-prandial glucose if HbA1c was beyond 
the target despite pre-prandial glucose levels 
 
In pregnancy:  
HbA1c 
Pre-prandial plasma glucose 
Post-prandial plasma glucose 
 
6% 
60-99 mg/dL 
100-129 mg/dL 
Table 1. Recommended objectives for glycaemia control, in patients with diabetes 
3. Glucose monitoring in patients with diabetes 
SCCG is an essential component of intensive treatment, and the core of the DCCT 
publication is the enormous increase in its diffusion and utilisation. As a result of this, the 
new technologies applied to these systems have evolved rapidly, giving rise to successive 
new measures on the market.   
HbA1c is the reference pattern to assess long-term glycaemia control and, together with the 
measured glucose, determines the guidelines for adjustments in treatment of diabetes by the 
attending physician.  
As we have stated earlier, in the past few years there has been in increase in the evidence 
showing the influence of post-prandial hyperglycaemia and glycaemia control, on the 
development of diabetic complications (Ceriello, 2003). 
SCCG consists of determining the capillary blood glucose of the patient, using the 
glucometer. It carries information complementary to HbA1c levels, such as fasting and post-
prandial glucose, detection of hypoglycaemia, information on the daily glucose variability, 
etc. This enables optimisation of treatment, above all in patients receiving intensive therapy. 
However, the information provided by the glucometer refers to a specific moment in time. 
For greater and better information on glycaemic changes there needs to be continuous 
glucose monitoring systems (CGMS) that perform several measurements per hour and, as 
such, produce averaged information over the course of the day. 
3.1 Indications for self-monitoring of glycaemia in patients with DM type 1 
Type 1 diabetes is characterised by frequent fluctuation in glycaemia. SCCG is the method–
of-choice and the timing is decided according the needs of the individual patient as well as 
the targets of the therapeutic regimen. There are no studies that demonstrate the efficacy of 
SCCG alone in improving the glycaemia control in patients with DM type 1, but they are an 
integral part of the treatment. The results of the DCCT study demonstrated that intensive 
treatment is the most appropriate option for the majority of patients with DM type 1. The 
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two modalities of intensive treatment (multiple doses of insulin and continuous subcutaneous 
infusion of insulin) involved targets of glycaemia control close to normality, with a higher risk 
of hypoglycaemia (DCCT, 1993). To prevent episodes of asymptomatic hypoglycaemias and 
hyperglycaemias and, as such, to perform an appropriate adjustment of the insulin dose, it is 
necessary to frequently supervise the glycaemic levels. In the DCCT study there was a need for 
at least 4  SCCG measurements per day (pre-prandial and at bedtime) and post-prandial 
measurements were performed when the levels of HbA1c were not appropriate despite the 
values of the pre-prandial SCCG values being within the pre-established control targets. 
Further, a SCCG measurement was indicated at 3:00 a.m. once a week. 
It is not clear what would be the optimum frequency of the capillary glucose measurements 
in patients with DM type 1, although there are various studies that have demonstrated that 
the increase in the self-control of glycaemia improves the metabolic control in these patients 
Currently, the majority of patients with DM type 1 and with gestational diabetes  treated 
with insulin need to have at least 3 SCCG per day (ADA, 2011) (grade A evidence), which 
should be individualised according to the characteristics of the patient and the therapeutic 
targets. In general, it is recommended that measurements regularly before meals and, on 
occasions, one or two hours after, and at night-time, provide information that is very useful 
for therapeutic optimisation (Bergenstal & Gavin, 2005).  
The latest clinical practice guide of the American Diabetes Association (ADA) establishes the 
following recommendations based on the scientific evidence (ADA, 2011): 
- Achieving a strict glycaemia control requires SCCG as an integral part of the 
therapeutic strategy (grade A evidence). 
- The patients treated with multiple doses of insulin need to perform SCCG 3 or more 
times a day (grade A evidence). 
- In patients treated with les than 3 doses of insulin, oral agents or single diabetic 
treatment, the SCCG is useful in achieving glycaemia control targets within the context 
of a specific educative program (grade E evidence). 
- To achieve the targets of post-prandial glycaemia control there needs to post-prandial 
SCCG performed (grade E evidence). 
- There is a need to instruct the patient on the usefulness of the SCCG, and to evaluate 
the technique and its use regularly so that the data obtained can be used in treatment 
adjustment (grade E evidence).     
3.2 Modalities of self-monitoring of glycaemia 
3.2.1 Self-monitoring the level of blood sugar using the glucometer 
SCCG requires a capillary blood sample obtained, usually, from finger-prick using a micro-
lancet and using a glucose meter. The majority of glucose meters currently available 
generate plasma values by the device reader, or directly in plasma, or by multiplying the 
whole blood value by 1.12 so that the value is comparable with that from the laboratory 
(Valeri et al., 2004). 
The measurement of glucose using the modern enzymatic methods (hexokinase or glucose 
oxidase) generates a rapid, reliable and precise measurement. The strips impregnated with 
these enzymes collect the blood sample and are read by the device in a short period of time 
(Goldstein et al., 2004).  
The majority of machines have a memory to save the previous results, and some even have 
the option of downloading to a computer and with printer graphics to enable the analysis of 
the data and to optimise the metabolic self-monitoring. Some devices enable patients to 
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record data such as the medication dose or the presence of symptoms. The most recent are 
smaller sized and require less quantity of blood for the analysis. For patients with impaired 
sight, there are devices that can adapt to voice synthesizer to deliver an audible version of 
the result. Most results can be obtained within about  5 seconds, depending on the 
characteristics of the apparatus (Bode et al., 2001). 
In some countries such as the USA, there are currently available certain glucometers that use 
other different sites than that of the finger to obtain the blood sample, in an attempt to 
reduce the discomfort of the finger-prick. In a study performed on one of these devices that 
obtained blood from the arm it is noted that reliable results were obtained that were less 
painful than the finger prick (Fineberg et al., 2001).   
3.2.2 Continuous monitoring of glucose - glucose sensors 
Over the last decade the SCCG system has been the only measurement available for the 
monitoring of glycaemia levels. Despite its unquestioned usefulness, it is an invasive 
technique, tedious for the patient, generates limited information at any specific time, and 
without additional information to establish trends. 
The concentration of glucose in the interstitial tissues is reflected in its concentration in 
capillary and venous blood, since the glucose diffuses into interstitial tissue to equilibrate 
both compartments. Based on this, the CGMS measures the glucose concentration in the 
interstitial liquid of the subcutaneous cellular tissue in a minimally invasive manner, using a 
sensor subcutaneously located. The CGMS can detect glycaemia oscillations continuously, 
such that maximum information can be generated on the direction, magnitude, duration, 
frequency and possible causes of the fluctuations of glycaemia over the long-term course of 
the day. Hence, it is very useful in optimising the treatment of patients with diabetes (Maran 
et al., 2005) (Garg, 2009). It precludes the limitations of information of the CGMS system of 
intensive treatment in the cases of detection in periods of inadvertent hypo- and 
hyperglycaemia (Klonoff, 2005). However, the sensors currently available do not have the 
precision of capillary glucometers and, hence, the use is approved as a complement, and not 
as a substitution, for SCCG. 
The invasive intravascular sensors measure plasma glucose directly and has been used to 
monitor hospitalised patients. However, there have not been any studies published on their 
functioning and usefulness in extended groups of patients (Klonoff, 2005). 
3.2.2.1 Types of glucose sensors 
Continuous monitoring of glucose was introduced in the 1970s, with a complex system 
termed biostator or artificial pancreas. Subsequently, new generation sensors appeared, with 
mixed results.  
Currently, there are 4 types of CGMS approved by the FDA available on the international 
market:  CGMS® (Continuous Glucose Monitoring System) such as the Guardian®, the 
Guardian Real Time®, the Paradigm Real Time® (Medtronic MiniMed, Northridge, CA, 
USA); the GlucoDay® system (Menarini Diagnostics, Florence, Italy); the Seven® system 
(DexCom Inc., San Diego, CA, USA); and the Freestyle Navigator® monitor (Abbott 
Laboratories, Alameda, CA, USA) (Gross et al., 2000). Table 2 compares the main features of 
the currently available systems. 
CGMS, approved by the FDA in 1999 was the first generation of sensors commercialised 
and, as such, the most widely used and, for which, there is the most clinical experience 
available. It is composed of a subcutaneous sensor and an external monitor. It needs to be 
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 Guardian, 
Guardian RT, 
Paradigm RT 
Glucoday Freestyle 
Navigator 
Seven System 
Range of glucose values 
(mg/dL) 
40-400 40-400 20-500 40-400 
Life-span of sensor (days) 3 in USA/ 6 in 
Europe 
2 5 7 
Warm-up period (hours) 2 2 10 (1 for latest 
system) 
2 
Calibration frequency Every 12 h One point Post-insertion:
-10, 12, 24, 72h 
-1, 2, 10, 24, 
72h (latest 
system) 
Every 72 
hours 
Sensor device Amerometric 
sensor 
Microdialysis 
glucose 
Amperometric 
sensor 
Amperometric 
sensor 
Results timing Retrospective Retrospective 
and Real time 
Real Time Real Time 
 
Sensor site 
 
In situ External In situ In situ 
Frequency of blood 
glucose display (min) 
5 3 1 5 
Rate-of-change arrows Yes No Yes Yes 
Integrate with pump Yes (Paradigm RT) No No No 
Accuracy (error grid) (%) 
 
61.7-76.3 64-88 76.3-81.7 70.4 
Limitations - Life span of 3 
days (USA) 
- Update 
glycaemia data on 
the screen every 5 
minutes 
- Calibrations are 
required every 2- 3 
days 
- Large 
system 
- Life span of 
2 days 
- Skin 
irritation 
- No rate- of- 
change 
arrows 
- Large sensor 
and transmitter
- Warm- up 
period of 10 
hours (first 
sensor)-  
- Calibration 
time 
programming 
required 
- Must use 
Freestyle strips 
for calibration 
- High cost 
-  Update 
glycaemia 
data on the 
screen every 5 
minutes 
- Does not 
permit 
selecting 
specific points 
above 
Table 2. Main features of the currently available CGMS devices (Torres et al, 2010) 
calibrated a minimum of 4 times a day using measured capillary glucose levels, presenting 
an out-of-phase between the level of glycaemia and the sensor signal of about 4 minutes 
(Gross et al., 2000). 
In the past few years, progressively improved new models have been developed. In 2004, 
the FDA approved the Guardian Monitor, with improvements on the previous system that 
included an alarm not only to signal hyperglycaemia but also for hypoglycaemia. One year 
later the Guardian MiniMed Real Time appeared on the market: It was the first continuous 
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glucose monitor that provided the measurements of glucose in real time, every 5 minutes, 
and with direct connection to a CSII. The Paradigm Real Time was approved in 2006 as the 
first sensor integrated with a CSII (Paradigm REAL-time 522/722) enabling it to create a 
closed circuit. More recently, MiniMed Paradigm Veo® system has been commercialised. It 
includes CSII with a CGMS with a mechanism that enables the infusion of insulin to be 
delayed when the levels of glucose are below the specified range. All these systems require 
at least 2 calibrations per day. 
Another type of sensor known as the GlucoDay® system became available on the market in 
2002. Its system is based on the technique of micro-dialysis applied to the interstitial fluid 
that, as has been commented-upon above, provides a reading of the glucose concentration in 
the subcutaneous cellular tissue that is very similar to the plasma value (Poscia et al.,2003; 
Varalli et al., 2003). The data collected can be visualised permanently in real time and to be 
used subsequently for different analyses regarding the behaviour of the glucose 
concentrations, such as its graphic representation. This system shows high precision and 
reliability, including at low glucose concentrations (Maran et al., 2002). 
The Seven System® was approved by the FDA in 2007. It enables real time readings with 
measurements performed every 5 minutes and with a latency of 12 hours. It is the only one 
proven for use over a period of 7 days. The results can be stored for subsequent analyses. 
The system includes alarms that can be programmed not only for hyperglycaemia but also 
for hypoglycaemia. It needs to be calibrated every 12 hours with capillary glucose values. A 
new version is the Seven Plus System which has improved not only the functionality but 
also has many additional functions included.  
The latest system approved by the FDA in 2008 is the Freestyle Navigator® which has 
introduced important improvements to the CGM system (McGarraugh, 2009). It enables 
readings in real time following a latency period of 10 hours (1 hour in the more advanced 
versions). The concentration of glucose is measured every minute and enables analyses to be 
made every 10 minutes. The calibration requires capillary glucose measurement (only 4-5 in 
the first period). It has alarms not only for excessively elevated glucose levels but also for 
glucose decrease. 
3.2.2.2 Clinical indications for continuous glucose monitoring (CGM) 
The clinical applications for continuous glucose monitoring (CGM) have not, as yet, been 
well established. The system can be useful in determining patterns of glycaemia over a 24h 
period and to detect inadvertent hypoglycaemia. However, its role in improving control of 
diabetes is, as yet, unclear. 
Currently, there are studies and preliminary data on the possible uses; the most extensive 
studies have focused on the detection of asymptomatic hypoglycaemia. Several studies show 
an elevated frequency of asymptomatic hypoglycaemia, especially during the nocturnal period 
and, above all, in patients with DM type 1, detected using CGMS, which have been 
underestimated with the conventional self-monitoring systems (DeVries et al., 2004). The 
CGMS also captures values of glucose which can change over a short period of time and, for 
which, it is not always practical to wait months to evaluate the reductions in the levels of 
HbA1c. CGM can show the time during which the patients remain in the glucose range that is 
normal, low or elevated. These values can be more useful than a single point when integrating 
the data such as the HbA1c levels. Prolonged exposure to intermediate levels of glucose may 
be preferred in some patients compared to the frequent peaks of hyperglycaemia and 
hypoglycaemia. This can obviate therapeutically targeting different HbA1c levels in response 
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to oscillating levels of glucose. The CGMS can detect these oscillations as well as measure the 
mean amplitude and the index of variability of the glycaemia. As such, predictive information 
on trends during the different times of the day can be obtained (Manuel-y-Keenoy et al., 2004). 
The CGMS can also be used to evaluate the response of the glycaemia profile to specific 
treatment or therapeutic modalities such as, for example, the use of multiple doses of insulin 
vs. the CIIS (Weintrob et al., 2004). There are several studies that show the usefulness of 
CGMS in modifying treatment and achieving better metabolic control (Edelman et al., 2009; 
Hirsch et al., 2008; Leinung et al., 2010). Some authors consider this its most important use. 
In adolescents, apart from being a useful tool to improve glycaemia control, it also promotes 
communication and motivation of the patient (Schaepelynck-Bélicar et al., 2003) .  
According to the data available, beneficial effects in metabolic control can be exercised in 
pregnant women with diabetes, but more studies are necessary to evaluate the reality of 
reducing perinatal complications (Festin,  2008). 
As such, the possible indications of CGM comprise those situations that require detailed 
information on the fluctuations of glycaemia: diagnostic confirmation and management of 
hypoglycaemia (undetected hypoglycaemias or nocturnal hypoglycaemias); therapeutic 
adjustments in patients who do not achieve the control targets (discrepancy between HbA1c 
and capillary glycaemia, pregestational diabetes); diabetic educational tool (impact of intake 
on the glycaemia profile), physical exercise, intercurrent situations; diabetes and 
hospitalisation (unit for the treatment of the critically-ill patients and/or intensive coronary 
care), pancreatic tissue transplant and clinical investigation. 
According to the recommendations of the American Diabetes Association (ADA, 2011), the 
CGM can be indicated in selected adult patients with DM type 1 on treatment with intensive 
insulin therapy to decrease the level of HbA1c (recommendation grade A). As well, CGM 
can be indicated in children, adolescents, and young adults in whom the adherence to 
treatment would be high (recommendation grade C). In patients with inadvertent 
hypoglycaemias, the CGM would be indicated as a complement to the SCCG. 
3.2.2.3 Inconveniences 
Currently, the CGMS is approved for the use in supplementing SCCG due to the inherent 
problems: limited level of precision for the isolated measurement of glucose, above all, at 
decreased levels (Klonoff, 2004); the need to calibrate the sensor several times a day using 
capillary measurements; short period of use (2-7 days) (Kovatchev et al., 2008).  
Minimally invasive CGMS can present secondary effects related to the continuous measure 
of interstitial fluid. It can cause slight local distress at the site of catheter insertion which can 
occur on rare occasions. Further, because of its complicated technique, these systems require 
help from the health-care professional team (Tanenberg et al., 2004).  
The major limitation of CGMS is, however, the current absence of scientific evidence of its 
usefulness. Methodologically appropriate studies are necessary to evaluate precisely the 
impact of these systems on improving the metabolic control in patients with diabetes, and 
their effect on hypoglycaemia decrease. The use can be extended in the future but CGMS 
needs to be improved with respect to the accuracy of glucose measurement, convenience for 
the patient, integration with other technologies such as CIIS.  
4. Treatment of diabetes  
As commented-upon earlier, intensive therapy of DM type 1 has been consolidated as the 
therapeutic strategy of choice since it has been demonstrated to delay the appearance and 
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progression of the chronic complications (DCCT, 1993; Nathan et al., 2005). This strategy 
consists of multiple daily subcutaneous injections, or the use of CIIS with adjustment of 
insulin according to the intake of carbohydrates and the level of glycaemia (ADA, 2011).   
4.1 Treatment with multiple doses of insulin 
The objective of intensive insulin therapy is to arrive at levels of glycaemia close to that of 
normal, using a regimen of insulin similar to physiological conditions. To achieve this, basal 
insulin treatment (1 or 2 doses per day with intermediate or low insulin) is accompanied by 
pre-prandial bolus of quick-acting insulin which is adjusted according to the pre-prandial 
glycaemia and the intake of carbohydrates. To correctly fulfil this type of therapy, 
collaboration on the part of the patient is necessary and can be achieved with motivation 
and information using an appropriate program of diabetes education. As has been 
highlighted earlier, this type of treatment needs to be accompanied with frequent 
monitoring with capillary measurements. 
Intensive therapy is associated with more frequent hypoglycaemias. Since the DCCT 
publication, analogues of fast- and slow-acting insulins have been developed which, 
currently, form the basis of intensive treatment with multiple doses of insulin. These insulin 
analogues have been associated with a lower risk of hypoglycaemias, and a comparable 
decrease in HbA1c. Among the analogues of slow-acting insulin are glargine and detemir. 
Glargine insulin is almost identical to human insulin, except for certain modifications in the 
molecular structure that enables delaying the absorption in subcutaneous tissue resulting in 
prolonged duration without peaks of activity. It can be administered at any time of the day 
without impairing its effectiveness. Detemir insulin is another slow-acting analogue that has 
a fatty acid in its structure that enables it to bind to albumin in the subcutaneous tissue and 
its slow release prolongs its action in the blood stream. Both insulins, glargine and detemir, 
have similar efficacy, similar to the NPH, and are especially indicated in patients with 
recurring hypoglycaemias (Sing et al., 2009). 
The fast-acting insulin analogues have modifications in the molecular structure which facilitate 
more rapid absorption into the bloodstream. Currently, there are three fast-acting analogues 
(lispro, aspart and glulisine) whose duration of action and effects are similar. They commence 
action within 5-15 minutes of subcutaneous administration, with a maximum peak at 30-90 
minutes and a duration of 2-4 hours. Compared to standard insulin that begins its effects at 30-
45 minutes from injection and has a duration of 4-6 hours, the new fast-acting analogues 
decrease the post-prandial glucose peak more quickly, can be injected immediately before 
meals, and decrease hypoglycaemias (Plank et al., 2005; Porcellati et al., 2008). The election of 
one or other insulin for multiple dose therapy would depend on the characteristics of the 
patient. No one type of insulin has been elected as treatment-of-choice because a clear benefit 
on metabolic control has not as yet been demonstrated in a generic manner. 
4.2 Continuous Insulin Infusion Systems (CIIS) 
Pumps for CIIS are electro-mechanical, portable and small, with the administration of 
insulin from a reservoir at a programmable rate via a flexible catheter through a cannular 
inserted subcutaneously. This system delivers insulin continuously at a rhythm that is 
termed “basal rate” and which can be increased or decreased according to the requirements 
of the patient. In basal rate, the control of hepatic production of pre-prandial and overnight 
glucose is an objective. Further, the pump can provide specific amounts of extra “bolus” 
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insulin which can administered before the intake allows the post-prandial glycaemia to 
become elevated. It can, as well, correct specific increases in glycaemia caused by other 
circumstances. Insulins used in the CIIS are exclusively fast-acting. Standard human, and 
preferably, the analogues lispro, aspart and glulisine, are used since these offer less 
variability in absorption, and show a pharmacokinetic profile closer to that of the 
physiologic state (Hirsch, 2005; Radermecker & Scheen, 2004). 
Using CIIS in patients with DM type 1 began in the decade of the 1970s but, despite being 
effective in metabolic control, the initial devices had high risk of sepsis and thrombosis. At the 
start of the decade of the 1980s, evidence was communicated of an increase in mortality in 
patients having the CIIS; data that were not subsequently confirmed (Teutsch et al., 1984). The 
use of CIIS does not perform very well against the possibility of severe hypoglycaemia (Lock & 
Rigg, 1981) and frank ketoacidosis which was highlighted in some articles (Home & Marshall, 
1984). The impact of the results of the DCCT became decisive for the widespread use of insulin 
pumps. The study highlighted a significant reduction in the levels of HbA1c in patients treated 
with CIIS compared with those who received multiple daily doses of insulin (DCCT, 1995). 
Since then, the use of CIIS has accelerated exponentially, and what was a research tool has 
become an established type of treatment for selected patients with DM type 1 (Cummins et al., 
2010). On the other hand, the important technological development over the past few years has 
been to reduce the size of the pump considerably, to increase the benefits and to improve their 
safety. In the past decade, several studies have confirmed that therapy with CIIS has 
advantages in metabolic control while achieving greater decreases in the levels of HbA1c 
(Cummins et al., 2010; Pańkowska et al., 2009; Pickup & Sutton, 2008; Torres et al., 2009). 
Further, this improvement in glycaemia control is achieved with a lower quantity of insulin 
(Jeitler et al., 2008; Torres et al., 2009). Hence, CIIS has become established as the preferred 
modality of treatment, and an alternative to the multiple doses of insulin for those selected 
patients who do not achieve the target of glycaemia control with multiple injections of insulin 
(Bruttomesso et al., 2009).  
The patients with DM type 1 treated with multiple injections of insulin frequently present 
with the “dawn phenomenon” which consists of a sharp increase in glucose in the small 
hours of the morning; increase due to the increase in the counter-regulatory hormones that 
occur during this period and which are not sufficiently counteracted by long-acting insulin 
administered at bedtime. The therapy with CIIS, enables basal infusion to be anticipated and 
programmed, which can be useful in controlling this phenomenon by increasing the basal 
rhythm to that suitable for the individual’s needs (Bruttomesso et al., 2009; Cummins et al., 
2010).  
When CIIS therapy was used initially, there were cases of severe hypoglycaemia reported 
which brought the safety of the system into question (Lock & Rigg, 1981). In the subsequent 
years, the devices available were safer and used fast-acting analogues of insulin which 
resulted in reduction in the frequency of the severe hypoglycaemias. This form of treatment 
can achieve and maintain a grade of better metabolic control than can be achieved with 
multiple doses of insulin; the incidence of hypoglycaemia being significantly less, including 
at night (Pickup & Sutton, 2008; Torres et al., 2009). Brittle diabetes, with frequent and 
unannounced glycaemia oscillations, is improved with CIIS therapy.  
Oscillations in glycaemia are reduced due to the use of fast-acting insulin analogues whose 
absorption variability is much lower than other insulins, and with which there is the 
possibility of programming different rhythms of infusion (Bruttomesso et al., 2008; Pickup et 
al., 2006). 
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The accumulated experience of CIIS use in children and adolescents is very promising. This 
modality of treatment reduces the incidence of acute complications, not only hypoglycaemias 
but also ketoacidosis, together with improved metabolic control, increased adherence to the 
treatment and promotion of family involvement. Treatment with CIIS in the paediatric 
population is safe and efficacious and represents a valid option in selected patients of 
whatever age provided that there is always appropriate family and health-care professional 
support (Boland et al., 1999; Danne et al., 2008; DiMeglio et al., 2004). The results of the use of 
CIIS in pregestational diabetes have not been quite conclusive. Although some trials had 
observed benefits in metabolic control (Lapolla et al., 2003), more studies are needed to 
confirm their advantages in achieving maternal and foetal objectives, and regards their safety 
during the gestation (Cummins et al., 2010; Mukhopadhyay et al., 2007; Volpe et al., 2010). 
There are several studies that have found that the CIIS improves the quality-of-life of the 
patients because it allows better flexibility in relation to food intake and towards the conduct 
of various planned or unplanned activities. The considerable acceptance of this modality 
among users is due to the individual not being obliged to link food intake and social activities 
to insulin administration since several hours can elapse between the activities; as occurs when 
multiple dose insulin is used. The intake can be delayed or omitted and the content varied. 
Also, the intensity of the exercise can be modified as can the timing of the activity without 
compromising the glycaemia control target (EQuality1 Study Group, 2008; Radermecker & 
Scheen, 2004; Torres et al., 2009). The advantages of CIIS are summarised in Table 3. 
 
Improvement in metabolic control 
Correction of the dawn phenomenon 
Decrease in hypoglycaemias 
Improvement in brittle diabetes 
Effective in adults, adolescents and children 
Flexibility and improvement in quality-of-life 
Table 3. Advantages of CIIS 
Interruption of insulin delivery by mechanical failure in the system of infusion leads quickly 
to hypoglycaemia and ketoacidosis due to the absence of a subcutaneous deposit of insulin 
(Krzentowski et al., 1983). This and other similar circumstances  are preventable by training 
the individual to identify a potential episode, to warn and to treat the elevated levels of 
glycaemia (Guilhem et al., 2006). At the site of insertion of the cannular there may appear 
atrophy, hypertrophy, pruritus, erythema and infection. In the majority of cases the clinical 
picture is slight and related to inadequate hygiene in the techniques used. Systematic 
rotation and changing the catheter a maximum of every 3 days would decrease, or pre-
empt, these complications (Guilhem et al., 2006). The better strategy to prevent these 
complications is to instruct the patients using specific educative programs that highlight 
frequent monitoring of the glycaemia, objectives of glycaemia control, calculation of dietary 
carbohydrates and the adaptation of daily fluctuations in glycaemia induced by intake, 
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physical exercise and situations of stress or illness. Further, family help and social 
environment are important for outcomes (Jeandidier et al., 2008; Tamborlane et al., 2003).  
The indications for CSII treatment are not universally established. Appropriate patient 
selection is fundamental in minimising the risks that these devices can involve. The best 
results are obtained in psychologically stable patients, with sufficient intellectual capacity, 
highly motivated and supervised by a multi-disciplinary team. CIIS therapy requires a 
specifically formed team of healthcare professionals with sufficient time dedication to their 
patients not only for the training but also for clinical follow-up. The circumstances for CIIS 
treatment apply to any age in achieving good metabolic outcomes (Bruttomesso et al., 2009; 
Cummins et al., 2010). The indications more widely accepted are collected in Table 4 
 
HbA1c >7% despite good adherence to therapy with multi-injection systems 
Severe hypoglycaemias, recurrent, nocturnal or inadvertent 
Significant dawn phenomenon 
Brittle diabetes. Wide glycaemia variation, independent of HbA1c 
Planned pregnancy if no good control with multi-injection 
Need for flexible life-style 
Low insulin requirements (<20 UI/day) 
Table 4. Indications for CIIS 
4.3 CIIS monitoring 
Frequent monitoring of glycaemia is a highly positive factor in obtaining good results with 
CIIS therapy (Shalitin et al., 2010). The information provided by CGMS enables better 
adaptation not only to the rhythm of basal infusion but also to the bolus. If it is accepted that 
if the patients treated with CIIS are more motivated, the outcomes resulting from the 
application of CGMS in this group could be greater (Leinung et al., 2010; Raccah et al., 2009). 
Currently, better practical advantages are to be gained in the in situ subcutaneous sensors 
with continuous reading in real time which integrate the CGMS in a continuous infusion of 
insulin using wireless communication; the technique termed continuous interactive 
monitoring. In this mode, the users of CIIS can adapt the insulin infusion and diet to the real 
metabolic status. This is possible because the information generated by CGMS allows for the 
detection of inadvertent hypoglycaemias, information on trends and speed-of-change of 
glucose, and provides help in planning the bolus to reduce the duration of the 
hyperglycaemic episode (Hirsch, 2009). A recent innovation has consisted of semi-automatic 
models that, apart from integrating the insulin infusion and the CGMS, automatically 
incorporates the delay in infusion over 2 hours in case of having produced an alarm for 
hypoglycaemia but had not obtained a response from the user (Hirsch et al., 2008a). 
Real time information is an important advance in self-care by the patients but, as well, 
implies a challenge in applying this technology with safety and rigor. In the past 10 years 
the precision of these systems has improved and the durability of the sensor has increased 
up to 6-7 days. However, one important limitation is that none of the sensors currently 
available have the precision of the standard glucometers. This is because they do not 
measure the blood sugar directly but, rather, evaluate glucose in the subcutaneous 
interstitial fluid. The defects in precision are related to the low concentration of glucose in 
the interstitial fluid, the specific dynamics of the glucose in the capillary and interstitial 
fluids and the delays inherent in the measurement (Torres et al., 2010).  
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The patients with CIIS who are candidates for CGMS systems need to be very motivated 
and to have received verbal and written information in a program of therapeutic education. 
The effect is to avoid false expectations and to recognise the limitations of these systems. 
The educative program would be orientated towards training, management of the devices, 
and in the interpretation of the measurements of glucose in real time; all orientated towards 
achieving the euglycaemia state (Gilliam & Hirsch, 2009; Hirsch et al., 2008a; Juvenile 
Diabetes Research Foundation Continuous Glucose Monitoring Study Group, 2009a). In 
principle, the ideal candidate would be a patient with DM type 1, with excellent motivation 
and optimum therapeutic education, who has not been able to achieve HbA1c levels <7%. 
Several studies have demonstrated that the use of CGMS in patients with CIIS has 
advantages in metabolic control, with significant decreases in the levels of HbA1c 
(Bergenstal et al., 2010; Deiss et al., 2006; Hirsch et al., 2008b; Juvenile Diabetes Research 
Foundation Continuous Glucose Monitoring Study Group, 2008) and less glycaemia 
variability (Garg et al., 2006; Kordonouri et al., 2010). Some studies have, as well, 
demonstrated improvement in the frequency of hypoglycaemia (Garg et al., 2006; Juvenile 
Diabetes Research Foundation Continuous Glucose Monitoring Study Group, 2009b; 
Leinung et al., 2010). The best results have been obtained in relation of adherence to the 
CGMS systems; continuous use being more efficient than intermittent use (Hirsch et al., 
2008b; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study 
Group, 2008, 2009a; Raccah et al., 2009) but, in practice, can be more difficult to fulfil 
(O'Connell et al., 2009). 
A list of possible indication for the use of CGMS is summarised in Table 5 (American 
Diabetes Association, 2011; Fabiato et al., 2009). 
 
Patients with DM type 1, excellent motivation and optimum therapeutic education, but 
who have not been able to achieve HbA1c <7% 
Severe hypoglycaemias, inadvertent hypoglycaemias or fear of hypoglycaemias that 
impede achieving the targets of glycaemia control 
Brittle diabetes 
Planned pregnancy with difficulties achieving appropriate glycaemia control 
Children and adolescents with significant glucose variability or frequent hypoglycaemias, 
severe or inadvertent despite adjustments of the therapies. It is indispensable that they 
and/or the family are motivated and have appropriate training. 
Table 5. Indications for interactive CGMS 
5. Future research  
The challenge to achieve an optimum metabolic control in type 1 DM is being progressively 
better addressed. New insulins and technological devices have been designed to mimic beta 
cell function. However, to translate these findings into the clinical practice new research and 
clinical trials are needed. Technological advances have enabled the development of new CIIS 
devices with better performance in programming and for calculating optimal dose of insulin 
required. Systems security alerts are getting better, and the availability of sensors that promote 
CIIS devices has been a promising development. A closed-loop system should include an 
implantable continuous glucose sensor, an insulin pump and an algorithm control leading to 
insulin infusion adjusted to the glucose concentrations (Kumareswaran et al., 2009). In the 
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future, combined use of insulin pumps and glucose sensors could become an effective and safe 
strategy, with minimal constraints in optimising metabolic control in diabetic patients to 
achieve glycaemia very close to normal (Hirsch, 2009; Keenan et al., 2010; Kowalski, 2009). 
Finally, we note that both CIIS therapy and the use of CGMS are expensive. The 
implementation of these technologies requires public health systems that have sufficient 
resources to initiate treatment and to ensure appropriate monitoring by the users. Further 
studies are needed on cost and effectiveness of these systems (Cummins et al., 2010; Fabiato 
et al., 2009; Huang et al., 2010).  
6. Conclusions  
Several prospective studies in Type 1 DM have demonstrated the tight association existing 
between glycaemia and the development of micro- and macro-angiopathy complications. 
The most significant study (the DCCT study) demonstrated that intensive treatment was 
accompanied by a reduction in the appearance and progression of the micro-vascular 
complications. Subsequent analyses of the DCCT study population demonstrated that the 
beneficial effects persisted even after the intervention and that they are extended to adverse 
cardiovascular events, as well. To achieve this objective, treatment of DM continues to be 
enriched by several novel therapeutic approaches. These have increased with the 
incorporation of insulin analogues and the introduction and optimisation of devices for the 
administration of insulin (continuous infusion system, CIIS) which achieves profiles of 
activity closer to the physiological equivalent. Several studies have demonstrated that the 
treatment with CIIS improves glycaemia variation with greater decrease in the HbA1c, less 
hypoglycaemias, and no increase in the frequency of ketoacidosis. Methods for evaluating 
response to treatment have been progressively improved. Recent clinical evidence has 
demonstrated that the glycaemia profile of the patients with DM, especially type 1 DM, is 
characterised by wide fluctuations related to physical activity, diet, and the specific 
treatment administered. The impact and the consequences of these variations are only 
partially known. Hence, the possibility of having continuous information available on 
glucose levels is an attractive option. Glucose sensors or CGMS provide maximum 
information on the changes in plasma glucose levels along the course of the day, and can be 
used in optimising treatment in patients with DM. However, the clinical applications of the 
CGMS have not, as yet, been well established.  
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